Abstract

The cis-regulatory effects responsible for cancer development have not been as extensively studied as the perturbations of the protein coding genome in tumorigenesis1,2. To better characterize colorectal cancer (CRC) development we conducted an RNA-sequencing experiment of 103 matched tumour and normal colon mucosa samples from Danish CRC patients, 90 of which were germline-genotyped. By investigating allele-specific expression (ASE) we show that the germline genotypes remain important determinants of allelic gene expression in tumours. Using the changes in ASE in matched pairs of samples we discover 71 genes with excess of somatic cis-regulatory effects in CRC, suggesting a cancer driver role. We correlate genotypes and gene expression to identify expression quantitative trait loci (eQTLs) and find 1,693 and 948 eQTLs in normal samples and tumours, respectively. We estimate that 36% of the tumour eQTLs are exclusive to CRC and show that this specificity is partially driven by increased expression of specific transcription factors and changes in methylation patterns. We show that tumour-specific eQTLs are more enriched for low CRC genome-wide association study (GWAS) P values than shared eQTLs, which suggests that some of the GWAS variants are tumour specific regulatory variants. Importantly, tumour-specific eQTL genes also accumulate more somatic mutations when compared to the shared eQTL genes, raising the possibility that they constitute germline-derived cancer regulatory drivers. Collectively the integration of genome and the transcriptome reveals a substantial number of putative somatic and germline cis-regulatory cancer changes that may have a role in tumorigenesis.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accessions

Data deposits

The RNA-sequencing and genotype data are deposited in the European Genome-phenome Archive (EGA, https://www.ebi.ac.uk/ega/) for controlled accesses; the study accession number is EGAS00001000854.

References

  1. 1.

    et al. Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957–959 (2013)

  2. 2.

    et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 497, 378–382 (2013)

  3. 3.

    et al. Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nature Genet. 44, 1084–1089 (2012)

  4. 4.

    , , & Epistatic selection between coding and regulatory variation in human evolution and disease. Am. J. Hum. Genet. 89, 459–463 (2011)

  5. 5.

    The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56–65 (2012)

  6. 6.

    Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012)

  7. 7.

    & Gitools: analysis and visualisation of genomic data using interactive heat-maps. PLoS ONE 6, e19541 (2011)

  8. 8.

    et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Scientific Rep. 2, 2650 (2013)

  9. 9.

    et al. Extracellular matrix protein βig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev. 22, 308–321 (2008)

  10. 10.

    et al. MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). J. Biol. Chem. 288, 9508–9518 (2013)

  11. 11.

    , , , & Identification of a colon mucosa gene that is down-regulated in colon adenomas and adenocarcinomas. Proc. Natl Acad. Sci. USA 90, 4166–4170 (1993)

  12. 12.

    et al. Alternative splicing of SLC39A14 in colorectal cancer is regulated by the Wnt pathway. Mol. Cell. Proteom. 10, M110.002998 (2011)

  13. 13.

    et al. Transcriptome and genome sequencing uncovers functional variation in humans. Nature 501, 506–511 (2013)

  14. 14.

    et al. Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. Cancer Res. 52, 5368–5372 (1992)

  15. 15.

    et al. The relationship between global methylation level, loss of heterozygosity, and microsatellite instability in sporadic colorectal cancer. Clin. Cancer Res. 11, 8564–8569 (2005)

  16. 16.

    et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer 91, 355–358 (2004)

  17. 17.

    et al. The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet. 7, e1002003 (2011)

  18. 18.

    & Cancer: Mutations close in on gene regulation. Nature 499, 35–36 (2013)

  19. 19.

    et al. Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer 6, 237 (2006)

  20. 20.

    et al. Transcription factor binding in human cells occurs in dense clusters formed around cohesin anchor sites. Cell 154, 801–813 (2013)

Download references

Acknowledgements

This study was designed under the SYSCOL project and samples were collected with informed consent in accordance with local law. This research is supported by grants from European Commission SYSCOL FP7 (UE7-SYSCOL-258236), European Research Council (ERC 260927), Louis Jeantet Foundation, Swiss National Science Foundation (130326, 130342), the NIH-NIMH (MH090941), the Danish National Advanced Technology Foundation, the John and Birthe Meyer Foundation, the Danish Council for Independent Research (Medical Sciences), the Danish Council for Strategic Research, the Danish Cancer Society, The Cellex Foundation, the Botin Foundation, the Fundacion Olga Torres, and the Health and Science Departments of the Catalan Government (Generalitat de Catalunya). The Danish Cancer Biobank is acknowledged for biological material. We thank S. Moran, D. Garcia and C. Arribas for their technical support. This study was also funded by Cancer Research UK and The Oxford Comprehensive Biomedical Research Centre (I.P.T.). Core infrastructure support to the Wellcome Trust Centre for Human Genetics, Oxford, was provided by grant (090532/Z/09/Z). Cancer Research UK provided funding individually to R.S.H. (C1298/A8362–Bobby Moore Fund for Cancer Research UK). This study made use of genotyping data from the 1958 Birth Cohort and NBS samples, kindly made available by the Wellcome Trust Case Control Consortium 2. The computations were performed at the Vital-IT (http://www.vital-it.ch) Center for high-performance computing of the SIB Swiss Institute of Bioinformatics.

Author information

Affiliations

  1. Department of Genetic Medicine and Development, University of Geneva Medical School, 1211 Geneva, Switzerland

    • Halit Ongen
    • , Pedro G. Ferreira
    • , Alexandra Planchon
    • , Ismael Padioleau
    • , Deborah Bielser
    • , Luciana Romano
    •  & Emmanouil T. Dermitzakis
  2. Institute for Genetics and Genomics in Geneva (iGE3), University of Geneva, 1211 Geneva, Switzerland

    • Halit Ongen
    • , Pedro G. Ferreira
    • , Alexandra Planchon
    • , Ismael Padioleau
    • , Deborah Bielser
    • , Luciana Romano
    •  & Emmanouil T. Dermitzakis
  3. Swiss Institute of Bioinformatics, 1211 Geneva, Switzerland

    • Halit Ongen
    • , Pedro G. Ferreira
    • , Alexandra Planchon
    • , Ismael Padioleau
    • , Deborah Bielser
    • , Luciana Romano
    •  & Emmanouil T. Dermitzakis
  4. Department of Molecular Medicine, Aarhus University Hospital, 8000 Aarhus, Denmark

    • Claus L. Andersen
    • , Jesper B. Bramsen
    • , Bodil Oster
    • , Mads H. Rasmussen
    •  & Torben F. Orntoft
  5. Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), 08908 Barcelona, Catalonia, Spain

    • Juan Sandoval
    • , Enrique Vidal
    •  & Manel Esteller
  6. Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK

    • Nicola Whiffin
    •  & Richard S. Houlston
  7. Nuffield Department of Clinical Medicine and Oxford NIHR Comprehensive Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN, UK

    • Ian Tomlinson
  8. Department of Physiological Sciences II, School of Medicine, University of Barcelona, 08007 Barcelona, Barcelona, Spain

    • Manel Esteller
  9. Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain

    • Manel Esteller

Authors

  1. Search for Halit Ongen in:

  2. Search for Claus L. Andersen in:

  3. Search for Jesper B. Bramsen in:

  4. Search for Bodil Oster in:

  5. Search for Mads H. Rasmussen in:

  6. Search for Pedro G. Ferreira in:

  7. Search for Juan Sandoval in:

  8. Search for Enrique Vidal in:

  9. Search for Nicola Whiffin in:

  10. Search for Alexandra Planchon in:

  11. Search for Ismael Padioleau in:

  12. Search for Deborah Bielser in:

  13. Search for Luciana Romano in:

  14. Search for Ian Tomlinson in:

  15. Search for Richard S. Houlston in:

  16. Search for Manel Esteller in:

  17. Search for Torben F. Orntoft in:

  18. Search for Emmanouil T. Dermitzakis in:

Contributions

H.O., C.L.A., J.B.B., T.F.O. and E.T.D. designed the study. H.O. and E.T.D. coordinated the project. H.O., J.B.B., A.P., I.P., D.B., L.R. and M.H.R. participated in RNA-sequencing data production. J.S., E.V. and M.E. designed and conducted the methylation experiment. N.W., I.T. and R.S.H. conducted the CRC GWAS. H.O. and P.G.F. analysed the data. H.O., C.L.A. and E.T.D. drafted the paper.

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Halit Ongen or Emmanouil T. Dermitzakis.

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    This file contains supplementary Methods, Supplementary Figures 1-28 and additional references.

Excel files

  1. 1.

    Supplementary Tables

    This file contains Supplementary Tables 1-13.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nature13602

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.